0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Observation |

Omalizumab Treatment of Vernal Keratoconjunctivitis

Enrico Heffler, MD, PhD1; Giuseppe Picardi, MD1; Maria Teresa Liuzzo, MD1; Maria Provvidenza Pistorio, BSc1; Nunzio Crimi, MD, PhD1
[+] Author Affiliations
1Unit of Respiratory Medicine and Allergology, Department of Clinical and Experimental Medicine, Azienda Ospedaliero Universitaria Policlinico–Vittorio Emanuele Hospital, University of Catania, Catania, Italy
JAMA Ophthalmol. 2016;134(4):461-463. doi:10.1001/jamaophthalmol.2015.5679.
Text Size: A A A
Published online

Extract

This report describes 2 patients with vernal keratoconjunctivitis without concomitant asthma who underwent systemic treatment with omalizumab.

Vernal keratoconjunctivitis (VKC) is a severe ocular, chronic, relapsing disease that can result in loss of visual acuity and blindness. Treatment with topical antihistamines, mast-cell stabilizers, corticosteroids, or even topical immunosuppressors (ie, cyclosporine or tacrolimus) frequently does not improve VKC symptoms, and partial control of symptoms with oral corticosteroids can induce severe adverse events with long-term use.1 Omalizumab is a humanized monoclonal antibody directed toward IgE and is approved for treating severe allergic asthma and severe chronic idiopathic urticaria.2

Figures in this Article

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview

Figures

Place holder to copy figure label and caption
Figure 1.
Clinical and Cytologic Results of Omalizumab Treatment

Changes in the visual analog scale (VAS) (range, 0 to 9; higher scores indicate worse symptoms) for ocular symptoms and in conjunctival eosinophil levels (bars) before and during omalizumab treatment in 2 patients with severe vernal keratoconjunctivitis. Both patients underwent subcutaneous treatment for 6 months. To convert eosinophil levels to a proportion of 1, multiply by 0.01.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.
Results of Conjunctival Cytologic Examination

Conjunctival scrape smears for cytologic examination were obtained from each patient at each visit. The eosinophil level in patient 1 was 68% before and 3% after omalizumab treatment; in patient 2, the eosinophil level was 51% before and 0% after omalizumab treatment (to convert eosinophil levels to a proportion of 1, multiply by 0.01) (May-Grünwald-Giemsa, original magnification ×1000).

Graphic Jump Location

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

387 Views
0 Citations
×

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
JAMAevidence.com

Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice, 3rd ed

brightcove.createExperiences();